Freeze and fry: new device tackles lung cancer in one procedure

NCT ID NCT07530744

Not yet recruiting Disease control Sponsor: Elisabethinen Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a device that uses both cold and radiofrequency to treat lung tumors during a standard bronchoscopy. Twenty people with early-stage lung cancer will receive the treatment before surgical removal of the tumor. The goal is to see if the device can safely and effectively destroy cancer cells, potentially improving outcomes.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: HybridTherm® system (cryotherapy and radiofrequency ablation device)
What this could lead to: If successful, this could provide a more effective way to treat lung tumors during routine bronchoscopy, potentially improving outcomes for patients with early-stage lung cancer.
What could go wrong: This is a small, early-stage registry study with only 20 participants, so results may not apply to all patients. There is a risk of bleeding or other complications from the procedure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CRYOTHERAPY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CRYOTHERAPY NSCLC RFA

Contacts and locations

Locations

Ordensklinikum Linz Elisabethinen

Linz, Austria

More trials for these conditions

Other studies related to the condition(s) this trial covers.